Tapewire

Nasdaq · USD

ABOS

Acumen Pharmaceuticals, Inc.

Export transactions ↓
Tapewire entity
6281
SEC CIK
0001576885
Parsed reports
140

Last 12 months

Inside the activity.

0 purchase rows · 48 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 2026042
Feb 202601
Mar 202601
Apr 202600
May 202600
Jun 202604
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
January 16, 2026 Filed Jan 21, 2026 18:29 UTC
Schacterle AmyChief Regulatory Officer
GrantEmployee Stock Option (right to buy) · Derivative 126,900 $0.00 Strike: $1.89 $0.00
Disclosure

SEC source: 0001628280-26-002957 · wk-form4_1769038189.xml · derivative · entry 2

Schacterle Amy · CIK 0002042021 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,900

Underlying: Common Stock · 126,900 shares

Expires 2036-01-16

F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
January 16, 2026 Filed Jan 21, 2026 18:29 UTC
Schacterle AmyChief Regulatory Officer
GrantCommon Stock 84,600 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-002957 · wk-form4_1769038189.xml · nonDerivative · entry 1

Schacterle Amy · CIK 0002042021 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,303

F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
January 16, 2026 Filed Jan 21, 2026 18:29 UTC
Doherty James J.President and CDO
GrantEmployee Stock Option (right to buy) · Derivative 250,300 $0.00 Strike: $1.89 $0.00
Disclosure

SEC source: 0001628280-26-002956 · wk-form4_1769038162.xml · derivative · entry 2

Doherty James J. · CIK 0002009718 · President and CDO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,300

Underlying: Common Stock · 250,300 shares

Expires 2036-01-16

F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
January 16, 2026 Filed Jan 21, 2026 18:29 UTC
Doherty James J.President and CDO
GrantCommon Stock 166,867 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-002956 · wk-form4_1769038162.xml · nonDerivative · entry 1

Doherty James J. · CIK 0002009718 · President and CDO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,900

F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
January 16, 2026 Filed Jan 21, 2026 18:31 UTC
Siemers EricChief Medical Officer
GrantEmployee Stock Option (right to buy) · Derivative 148,700 $0.00 Strike: $1.89 $0.00
Disclosure

SEC source: 0001628280-26-002959 · wk-form4_1769038268.xml · derivative · entry 2

Siemers Eric · CIK 0001866239 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,700

Underlying: Common Stock · 148,700 shares

Expires 2036-01-16

F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
January 16, 2026 Filed Jan 21, 2026 18:31 UTC
Siemers EricChief Medical Officer
GrantCommon Stock 99,133 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-002959 · wk-form4_1769038268.xml · nonDerivative · entry 1

Siemers Eric · CIK 0001866239 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 258,597

F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
January 16, 2026 Filed Jan 21, 2026 18:31 UTC
Meisner Derek MChief Legal Officer & Corp Sec
GrantEmployee Stock Option (right to buy) · Derivative 148,700 $0.00 Strike: $1.89 $0.00
Disclosure

SEC source: 0001628280-26-002960 · wk-form4_1769038296.xml · derivative · entry 2

Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,700

Underlying: Common Stock · 148,700 shares

Expires 2036-01-16

F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
January 16, 2026 Filed Jan 21, 2026 18:31 UTC
Meisner Derek MChief Legal Officer & Corp Sec
GrantCommon Stock 99,133 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-002960 · wk-form4_1769038296.xml · nonDerivative · entry 1

Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,933

F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
January 16, 2026 Filed Jan 21, 2026 23:32 UTC
Zuga MattCFO & Chief Business Officer
GrantEmployee Stock Option (right to buy) · Derivative 148,700 $0.00 Strike: $1.89 $0.00
Disclosure

SEC source: 0001628280-26-002961 · wk-form4_1769038322.xml · derivative · entry 2

Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,700

Underlying: Common Stock · 148,700 shares

Expires 2036-01-16

F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
January 16, 2026 Filed Jan 21, 2026 23:32 UTC
Zuga MattCFO & Chief Business Officer
GrantCommon Stock 99,133 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-002961 · wk-form4_1769038322.xml · nonDerivative · entry 1

Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 309,084

F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
January 16, 2026 Filed Jan 21, 2026 23:30 UTC
Barton RussellChief Operating Officer
GrantEmployee Stock Option (right to buy) · Derivative 126,900 $0.00 Strike: $1.89 $0.00
Disclosure

SEC source: 0001628280-26-002958 · wk-form4_1769038220.xml · derivative · entry 2

Barton Russell · CIK 0001867418 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,900

Underlying: Common Stock · 126,900 shares

Expires 2036-01-16

F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
January 16, 2026 Filed Jan 21, 2026 23:30 UTC
Barton RussellChief Operating Officer
GrantCommon Stock 84,600 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-002958 · wk-form4_1769038220.xml · nonDerivative · entry 1

Barton Russell · CIK 0001867418 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 207,869

F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
January 12, 2026 Filed Jan 12, 2026 18:50 UTC
OConnell Daniel JosephDirector · Chief Executive Officer
SaleCommon Stock 5,388 $1.73 $9,306.69
Disclosure

SEC source: 0001628280-26-001895 · wk-form4_1768261820.xml · nonDerivative · entry 3

OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 593,510

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 27, 2025.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.6700 to $1.8400. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 12, 2026 Filed Jan 12, 2026 18:51 UTC
Meisner Derek MChief Legal Officer & Corp Sec
SaleCommon Stock 8,548 $1.71 $14,658.11
Disclosure

SEC source: 0001628280-26-001896 · wk-form4_1768261867.xml · nonDerivative · entry 4

Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,800

F3 · shares: Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.

F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.6700 to $1.8400. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 09, 2026 Filed Jan 12, 2026 18:50 UTC
OConnell Daniel JosephDirector · Chief Executive Officer
SaleCommon Stock 12,941 $1.76 $22,831.81
Disclosure

SEC source: 0001628280-26-001895 · wk-form4_1768261820.xml · nonDerivative · entry 2

OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 598,898

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 27, 2025.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7100 to $1.8100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 09, 2026 Filed Jan 12, 2026 18:51 UTC
Meisner Derek MChief Legal Officer & Corp Sec
SaleCommon Stock 5,200 $1.76 $9,169.16
Disclosure

SEC source: 0001628280-26-001896 · wk-form4_1768261867.xml · nonDerivative · entry 3

Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,348

F3 · shares: Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7100 to $1.8150. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 08, 2026 Filed Jan 9, 2026 16:39 UTC
Doherty James J.President and CDO
SaleCommon Stock 6,467 $1.82 $11,768.65
Disclosure

SEC source: 0001628280-26-001636 · wk-form4_1767994762.xml · nonDerivative · entry 2

Doherty James J. · CIK 0002009718 · President and CDO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,033

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 08, 2026 Filed Jan 12, 2026 18:50 UTC
OConnell Daniel JosephDirector · Chief Executive Officer
SaleCommon Stock 8,143 $1.82 $14,815.37
Disclosure

SEC source: 0001628280-26-001895 · wk-form4_1768261820.xml · nonDerivative · entry 1

OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 611,839

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 27, 2025.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 08, 2026 Filed Jan 12, 2026 18:51 UTC
Meisner Derek MChief Legal Officer & Corp Sec
SaleCommon Stock 30,092 $1.82 $54,866.74
Disclosure

SEC source: 0001628280-26-001896 · wk-form4_1768261867.xml · nonDerivative · entry 2

Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,548

F3 · shares: Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 08, 2026 Filed Jan 12, 2026 18:51 UTC
Meisner Derek MChief Legal Officer & Corp Sec
SaleCommon Stock 6,819 $1.82 $12,379.21
Disclosure

SEC source: 0001628280-26-001896 · wk-form4_1768261867.xml · nonDerivative · entry 1

Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,640

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 08, 2026 Filed Jan 12, 2026 23:52 UTC
Zuga MattCFO & Chief Business Officer
SaleCommon Stock 6,888 $1.82 $12,512.74
Disclosure

SEC source: 0001628280-26-001898 · wk-form4_1768261959.xml · nonDerivative · entry 1

Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,951

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 08, 2026 Filed Jan 12, 2026 23:52 UTC
Barton RussellChief Operating Officer
SaleCommon Stock 3,530 $1.86 $6,561.56
Disclosure

SEC source: 0001628280-26-001897 · wk-form4_1768261937.xml · nonDerivative · entry 1

Barton Russell · CIK 0001867418 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,269

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 25, 2025.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.8000 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 07, 2026 Filed Jan 7, 2026 21:31 UTC
OConnell Daniel JosephDirector · Chief Executive Officer
SaleCommon Stock 37,755 $1.99 $74,981.43
Disclosure

SEC source: 0001628280-26-001263 · wk-form4_1767839464.xml · nonDerivative · entry 3

OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 619,982

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9500 to $2.0300. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 07, 2026 Filed Jan 7, 2026 21:30 UTC
Meisner Derek MChief Legal Officer & Corp Sec
SaleCommon Stock 10,070 $1.99 $20,035.27
Disclosure

SEC source: 0001628280-26-001262 · wk-form4_1767839440.xml · nonDerivative · entry 5

Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,459

F4 · shares: Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.

F7 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9500 to $2.0250. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 07, 2026 Filed Jan 7, 2026 21:30 UTC
Meisner Derek MChief Legal Officer & Corp Sec
SaleCommon Stock 1,700 $1.99 $3,378.92
Disclosure

SEC source: 0001628280-26-001262 · wk-form4_1767839440.xml · nonDerivative · entry 4

Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,529

F5 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.

F6 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9600 to $2.0200. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 02:31 UTC
Zuga MattCFO & Chief Business Officer
SaleCommon Stock 1,700 $1.99 $3,376.54
Disclosure

SEC source: 0001628280-26-001265 · wk-form4_1767839507.xml · nonDerivative · entry 4

Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 216,839

F5 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025.

F6 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9600 to $2.0100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 02:31 UTC
Zuga MattCFO & Chief Business Officer
SaleCommon Stock 4,105 $2.00 $8,189.48
Disclosure

SEC source: 0001628280-26-001265 · wk-form4_1767839507.xml · nonDerivative · entry 3

Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 218,539

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9500 to $2.0400. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 02:30 UTC
Barton RussellChief Operating Officer
SaleCommon Stock 1,700 $1.99 $3,378.07
Disclosure

SEC source: 0001628280-26-001261 · wk-form4_1767839412.xml · nonDerivative · entry 3

Barton Russell · CIK 0001867418 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,799

F4 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 25, 2025.

F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9550 to $2.0200. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 07, 2026 Filed Jan 9, 2026 16:38 UTC
Schacterle AmyChief Regulatory Officer
SaleCommon Stock 1,097 $1.98 $2,176.23
Disclosure

SEC source: 0001628280-26-001633 · wk-form4_1767994720.xml · nonDerivative · entry 1

Schacterle Amy · CIK 0002042021 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,703

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9550 to $2.0100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 07, 2026 Filed Jan 9, 2026 16:39 UTC
Doherty James J.President and CDO
SaleCommon Stock 1,700 $1.99 $3,379.43
Disclosure

SEC source: 0001628280-26-001636 · wk-form4_1767994762.xml · nonDerivative · entry 1

Doherty James J. · CIK 0002009718 · President and CDO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,500

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9550 to $2.0200. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Number of securities reported as beneficially owned by Mr. Doherty following the reported transaction reflects the correction of a typographical error in the Form 4 report filed January 7, 2025, which overreported the number of RSUs granted to Mr. Doherty on January 6, 2025, by 400 shares.

Read SEC document
January 06, 2026 Filed Jan 7, 2026 21:31 UTC
Siemers EricChief Medical Officer
SaleCommon Stock 6,834 $1.97 $13,442.48
Disclosure

SEC source: 0001628280-26-001264 · wk-form4_1767839485.xml · nonDerivative · entry 2

Siemers Eric · CIK 0001866239 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,464

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2024.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9400 to $1.9900. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 06, 2026 Filed Jan 7, 2026 21:31 UTC
OConnell Daniel JosephDirector · Chief Executive Officer
SaleCommon Stock 5,102 $1.97 $10,031.55
Disclosure

SEC source: 0001628280-26-001263 · wk-form4_1767839464.xml · nonDerivative · entry 2

OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 657,737

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9400 to $2.0000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 06, 2026 Filed Jan 7, 2026 21:30 UTC
Meisner Derek MChief Legal Officer & Corp Sec
SaleCommon Stock 3,801 $1.97 $7,476.57
Disclosure

SEC source: 0001628280-26-001262 · wk-form4_1767839440.xml · nonDerivative · entry 3

Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,229

F4 · shares: Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9400 to $2.0000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 06, 2026 Filed Jan 7, 2026 21:30 UTC
Meisner Derek MChief Legal Officer & Corp Sec
SaleCommon Stock 7,097 $1.97 $13,961.22
Disclosure

SEC source: 0001628280-26-001262 · wk-form4_1767839440.xml · nonDerivative · entry 2

Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,030

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2024.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9400 to $2.0000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 06, 2026 Filed Jan 8, 2026 02:31 UTC
Zuga MattCFO & Chief Business Officer
SaleCommon Stock 5,100 $1.97 $10,027.62
Disclosure

SEC source: 0001628280-26-001265 · wk-form4_1767839507.xml · nonDerivative · entry 2

Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 222,644

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9400 to $1.9900. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 06, 2026 Filed Jan 8, 2026 02:30 UTC
Barton RussellChief Operating Officer
SaleCommon Stock 3,618 $1.97 $7,114.44
Disclosure

SEC source: 0001628280-26-001261 · wk-form4_1767839412.xml · nonDerivative · entry 2

Barton Russell · CIK 0001867418 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,499

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9400 to $1.9900. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 05, 2026 Filed Jan 7, 2026 21:31 UTC
Siemers EricChief Medical Officer
SaleCommon Stock 4,000 $1.96 $7,834.80
Disclosure

SEC source: 0001628280-26-001264 · wk-form4_1767839485.xml · nonDerivative · entry 1

Siemers Eric · CIK 0001866239 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,298

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2024.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9100 to $1.9750. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 05, 2026 Filed Jan 7, 2026 21:31 UTC
OConnell Daniel JosephDirector · Chief Executive Officer
SaleCommon Stock 4,649 $1.97 $9,163.18
Disclosure

SEC source: 0001628280-26-001263 · wk-form4_1767839464.xml · nonDerivative · entry 1

OConnell Daniel Joseph · CIK 0001865136 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 662,839

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9000 to $2.0600. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 05, 2026 Filed Jan 7, 2026 21:30 UTC
Meisner Derek MChief Legal Officer & Corp Sec
SaleCommon Stock 4,000 $1.96 $7,838.00
Disclosure

SEC source: 0001628280-26-001262 · wk-form4_1767839440.xml · nonDerivative · entry 1

Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,127

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2024.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9200 to $1.9750. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 05, 2026 Filed Jan 8, 2026 02:31 UTC
Zuga MattCFO & Chief Business Officer
SaleCommon Stock 4,000 $1.96 $7,842.40
Disclosure

SEC source: 0001628280-26-001265 · wk-form4_1767839507.xml · nonDerivative · entry 1

Zuga Matt · CIK 0001790214 · CFO & Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 227,744

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9100 to $1.9750. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 05, 2026 Filed Jan 8, 2026 02:30 UTC
Barton RussellChief Operating Officer
SaleCommon Stock 4,000 $1.96 $7,832.40
Disclosure

SEC source: 0001628280-26-001261 · wk-form4_1767839412.xml · nonDerivative · entry 1

Barton Russell · CIK 0001867418 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,117

F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9100 to $1.9800. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 06, 2025 Filed Nov 10, 2025 21:49 UTC GrantStock Option (right to buy) · Derivative 50,000 $0.00 Strike: $1.90 $0.00
Disclosure

SEC source: 0001586660-25-000003 · wk-form4_1762811342.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2035-11-06

F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a three-year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date and shall vest and become immediately exercisable prior to the effectiveness of a change in control.

Read SEC document
June 04, 2025 Filed Jun 5, 2025 20:57 UTC GrantStock Option (right to buy) · Derivative 19,500 $0.00 Strike: $1.07 $0.00
Disclosure

SEC source: 0001576885-25-000080 · wk-form4_1749156801.xml · derivative · entry 2

Fountain Nathan B · CIK 0001869596 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2035-06-04

F2 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
June 04, 2025 Filed Jun 5, 2025 20:57 UTC GrantCommon Stock 12,800 $0.00 $0.00
Disclosure

SEC source: 0001576885-25-000080 · wk-form4_1749156801.xml · nonDerivative · entry 1

Fountain Nathan B · CIK 0001869596 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,050

F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
June 04, 2025 Filed Jun 5, 2025 22:05 UTC GrantStock Option (right to buy) · Derivative 19,500 $0.00 Strike: $1.07 $0.00
Disclosure

SEC source: 0001576885-25-000084 · wk-form4_1749160924.xml · derivative · entry 2

Stoppel Laura · CIK 0001865119 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2035-06-04

F3 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option and RSUs for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund"), R.A. Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement, as applicable, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock.

Read SEC document
June 04, 2025 Filed Jun 5, 2025 22:05 UTC GrantCommon Stock 12,800 $0.00 $0.00
Disclosure

SEC source: 0001576885-25-000084 · wk-form4_1749160924.xml · nonDerivative · entry 1

Stoppel Laura · CIK 0001865119 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,800

F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option and RSUs for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund"), R.A. Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement, as applicable, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock.

Read SEC document
June 04, 2025 Filed Jun 5, 2025 20:51 UTC GrantStock Option (right to buy) · Derivative 19,500 $0.00 Strike: $1.07 $0.00
Disclosure

SEC source: 0001576885-25-000078 · wk-form4_1749156630.xml · derivative · entry 2

Porter Derrell · CIK 0001706400 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2035-06-04

F2 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
June 04, 2025 Filed Jun 5, 2025 20:51 UTC GrantCommon Stock 12,800 $0.00 $0.00
Disclosure

SEC source: 0001576885-25-000078 · wk-form4_1749156630.xml · nonDerivative · entry 1

Porter Derrell · CIK 0001706400 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,800

F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
June 04, 2025 Filed Jun 5, 2025 22:12 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
GrantStock Option (Right to Buy) · Derivative 19,500 $0.00 Strike: $1.07 $0.00
Disclosure

SEC source: 0001415889-25-015836 · form4-06052025_100655.xml · derivative · entry 5

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 19,500

Underlying: Common Stock · 19,500 shares

Expires 2035-06-04

F7 · derivative.exercise_date: Represents the grant of an option to Dr. Stoppel pursuant to the Issuer's non-employee director compensation policy. The shares subject to the option will vest on the earlier of June 4, 2026 or the 2026 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the RSU and the option for the benefit of the Fund and the Nexus Fund II. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSU, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the RSU, the option and underlying common stock.

Read SEC document
June 04, 2025 Filed Jun 5, 2025 22:12 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
GrantCommon Stock 12,800 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-015836 · form4-06052025_100655.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 12,800

F1 · shares: Represents the grant of a restricted stock unit ("RSU") award to Laura Stoppel pursuant to the Issuer's non-employee director compensation policy. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of June 4, 2026 or the Issuer's 2026 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the RSU and the option for the benefit of the Fund and the Nexus Fund II. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSU, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the RSU, the option and underlying common stock.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.